Abstract 928P
Background
The prediction of early response in locally advanced nasopharyngeal carcinoma (LA-NPC) after concurrent chemoradiotherapy (CCRT) is indeed important for determining the need for timely consolidation therapy. Radiomics has helped medical imaging expand from diagnostic to a personalized clinical decision aid, while most traditional radiomics primarily focus on mono-sequence. Recently, multi-MR sequences model has shown better outcomes in the management of many cancers. However, the validation of a radiomic analysis of multi-MR sequences based on machine learning for this purpose is currently lacking for patients with LA-NPC after CCRT.
Methods
This study comprised 104 patients with LA-NPC, of which 70% were allocated for training and the remaining 30% were used for internal validation. We extracted radiomics features corresponding to each mono-sequences (T1, T1C, T2, DWI, and ADC), and then applied LASSO for feature selection and constructed the risk model using machine learning algorithms including SVM, Random Forest, ExtraTrees, XGBoost and LightGBM. Performance comparisons were made between mono-sequences and then feature fusion was performed to construct a multi-MR sequences model. Clinical features were numerically mapped and analyzed using machine learning algorithms similar to those in the Radiomics Model. Finally, we created a combined model that integrated the radiomics and clinical models to enhance clinical relevance, whose diagnostic effectiveness was evaluated using receiver operator characteristic (ROC) curves in the test cohort.
Results
In the training cohort, while the Clinic model achieved an Area Under the Curve (AUC) of 0.892 and the Fusion model reached 0.972, the Combined model excelled with an AUC of 0.990. Similarly, in the test cohort, the Combined model outperformed both the Clinic (AUC: 0.852) and Fusion models (AUC: 0.886), achieving an AUC of 0.900.
Conclusions
As a result, a combined model, which merges clinical and multi-MR sequences radiomics model, showed good performance for predicting early response of LA-NPC after CCRT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Jiangsu Province Entrepreneurship and Innovation Doctoral Talent Program and Jiangsu Province People's Hospital Clinical Capability Enhancement Project.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1015P - The efficacy and mechanism of pan-FGFR inhibitor (AZD4547) combined with immunoagonists or immunosuppressants in FGFR-positive tumors
Presenter: Qizhi Ma
Session: Poster session 03
1016P - Phase I study of SOF10 plus atezolizumab in patients with advanced/recurrent solid tumours
Presenter: Toshihiko Doi
Session: Poster session 03
1017P - Updated safety and efficacy from the phase I study of givastomig, a novel claudin 18.2/4-1BB bispecific antibody, in claudin 18.2 positive advanced gastroesophageal carcinoma (GEC)
Presenter: Samuel Klempner
Session: Poster session 03
1018P - Leveraging innate and adaptive immunity with AFM24 and atezolizumab in metastatic gastric cancer
Presenter: Omar Saavedra Santa Gadea
Session: Poster session 03
1019P - Bispecific PD1-IL2 antibody reshapes the inhibitory immune microenvironment of SMARCA4 mutant non-small cell lung cancer by reversing CD8+T cell exhaustion
Presenter: Bo Cheng
Session: Poster session 03
Resources:
Abstract
1020P - Highly potent and specific bivalent T cell engager (TCE) targeting PRAME on HLA-A*02:01
Presenter: Athanasia Dasargyri
Session: Poster session 03
1021P - Chemotherapy and hypomethylating agents enhance anti-tumor activity of PRAME ImmTAC
Presenter: Adel Benlahrech
Session: Poster session 03
1022P - A phase II trial of the IO102-IO103 vaccine plus pembrolizumab: Completed cohort for first-line (1L) treatment of advanced squamous cell carcinoma of the head and neck (SCCHN)
Presenter: Jonathan Riess
Session: Poster session 03
1023P - Long-term follow up of patients treated with a DNA vaccine (pTVG-HP) for PSA-recurrent prostate cancer
Presenter: Douglas McNeel
Session: Poster session 03
1024P - Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors
Presenter: Stephane Champiat
Session: Poster session 03